SCHEMBL3516407

SCHEMBL3516407

O=C(O)CNC(=O)c1c(O)ccc2nc(N3CCCCC3)cnc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 2/20 0.50
EGLN1 Q9GZT9 8/20 0.38
MAPK1 P28482 1/20 0.38
P2RX7 Q99572 1/20 0.38
FTO Q9C0B1 3/20 0.36
KDM5B Q9UGL1 2/20 0.36
KDM2A Q9Y2K7 2/20 0.36
KDM4C Q9H3R0 1/20 0.36
KDM3A Q9Y4C1 1/20 0.36
EGLN2 Q96KS0 1/20 0.36
MAPT P10636 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 2/20 0.36
NPC1 O15118 1/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
RAB9A P51151 1/20 0.36
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3576722 0.84 ALDH1A1 (0.40) MAPK1MAPTSMN1; SMN2ALDH1A1KDM4E
SCHEMBL3516662 0.80 EGLN3 (0.57) EGLN3EGLN1FTOKDM5BKDM2A
SCHEMBL3522309 0.78 EGLN3 (0.57) EGLN3EGLN1FTOKDM5BKDM2A
SCHEMBL3757200 0.76 EGLN3 (0.57) EGLN3EGLN1FTOKDM5BKDM2A
SCHEMBL3519887 0.75 EGLN3 (0.66) EGLN3EGLN1FTOKDM5BKDM2A
SCHEMBL3761711 0.74 EGLN3 (0.56) EGLN3EGLN1MAPK1FTOKDM5B
SCHEMBL3528847 0.74 EGLN3 (0.50) EGLN3EGLN1MAPK1FTOKDM5B
SCHEMBL3761490 0.73 EGLN3 (0.55) EGLN3EGLN1FTOKDM5BKDM2A
SCHEMBL3516845 0.73 EGLN3 (0.57) EGLN3EGLN1FTOKDM5BKDM2A
SCHEMBL3751358 0.73 EGLN3 (0.55) EGLN3EGLN1MAPK1FTOKDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US claimed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP claimed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO claimed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN3 2/4885EGLN1 6/4885MAPK1 2734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.